Assess whether to drop a secondary endpoint that will dominate the AdCom

SITUATION The working file is biosimilar analytical similarity report after a competitor label that just got a narrower indication. Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate has to name Proceed under protocol or Pause the pathway for this Pharma & Life Sciences Pharmacovigilance file.

DECISION Pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate must choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold using biosimilar analytical similarity report after a competitor label that just got a narrower indication.

HYPOTHESES TO TEST 1. Authorize Proceed under protocol now; biosimilar analytical similarity report already has the discriminator after a competitor label that just got a narrower indication. 2. Keep Pause the pathway in force until biosimilar analytical similarity report is completed after a competitor label that just got a narrower indication for pharmacovigilance medical reviewer. 3. Treat biosimilar analytical similarity report as Escalate safety review because both readings appear after a competitor label that just got a narrower indication. 4. Refuse a Pharma & Life Sciences close: pharmacovigilance medical reviewer does not have the decision to drop a secondary turns on in biosimilar analytical similarity report.

ANALYSIS REQUIRED 1. Separate an isolated adverse event from a systemic quality issue. 2. Test a protocol deviation versus a safety signal versus a filing gap on to drop a secondary. 3. Check whether biosimilar analytical similarity report supports the labeled claim pharmacovigilance medical reviewer would keep. 4. For this Pharma & Life Sciences Pharmacovigilance file, read biosimilar analytical similarity report against a competitor label that just got a narrower indication and write the one fact that would move to drop a secondary for pharmacovigilance medical reviewer.

RECOMMENDATION Choose Proceed under protocol / Pause the pathway / Escalate safety review / Hold on this Pharma & Life Sciences / Pharmacovigilance packet (biosimilar analytical similarity report after a competitor label that just got a narrower indication). Lead with the Pharma & Life Sciences option biosimilar analytical similarity report can support after a competitor label that just got a narrower indication, then the two facts that force it, then the Monday action for pharmacovigilance medical reviewer in a labeling team facing a boxed-warning debate.

COMMAND RETURNS - Bottom-line Pharma & Life Sciences option on to drop a secondary, then the evidence in biosimilar analytical similarity report, then the action for pharmacovigilance medical reviewer - Hypothesis scorecard against biosimilar analytical similarity report: supported / rejected / untestable - Missing page in biosimilar analytical similarity report after a competitor label that just got a narrower indication, if any - Regulatory or exam hook Pharmacovigilance would cite